CME: The changing landscape of acute COVID‑19 treatment
ACCREDITATION EXPIRED: June 07, 2024
Activity Description / Statement of Need:
In this online, self-learning activity:
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has upended life as humankind knows it, leading to over 668 million cases and more than 6.7 million deaths worldwide at the time of this writing. SARS-CoV-2 invades the nasal epithelium and lungs, leading to a variety of clinical presentations and outcomes during the acute infectious process, including asymptomatic disease; milder symptoms such as fever, cough, abdominal pain, anosmia, and ageusia; and, in severe cases, hypoxemia, acute respiratory stress disease, and death. Complications are not limited to the respiratory tract and may present as multi-organ involvement varying from acute cardiac injury, coagulopathies, and multisystem inflammatory syndrome. Some survivors of the disease must also grapple with post-COVID conditions (or “long COVID”), which can include a constellation of manifestations, such as fatigue and impaired cognitive function, and impair patient quality of life.
Target Audience:
HCPs including: hospitalists and other primary care physicians, infectious disease physicians, pulmonologists, and critical care physicians; physician assistants, nurse practitioners, and pharmacists in those areas of specialty; and any other healthcare professionals with an interest in or who clinically encounter patients with acute COVID-19 infection.
Commercial Support Disclosure: This program is supported by an educational grant from Gilead.
This activity is free of charge.
Release Date: June 07, 2023 -- Expiration Date: June 07, 2024
Faculty: Michael Niederman, M.D., MACP, FCCP, FCCM, FERS
Agenda
|
Faculty introduction and disclosures |
|
Overview of Acute COVID‑19 · Brief primer on SARS CoV-2 o Shifting viral antigenicity o Effects of variants and subvariants on therapeutic options o Barrier to resistance for small molecules vs monoclonal antibodies · COVID‑19 diagnosis and risk assessment o CDC testing recommendations - Advantages and disadvantages of at-home tests o Assessing disease severity o Risk factors for progression to severe disease, including hospitalization and death |
|
Acute COVID-19 Treatment · NIH recommendations for COVID‑19 clinical management o Symptomatic management o Treatment for nonhospitalized patients o Treatment for hospitalized patients o Determining appropriate treatment setting o Patient counseling - CDC isolation recommendations - Symptoms to monitor - Promoting uptake and adherence to antivirals · Drugs for nonhospitalized patients o Shift from monoclonal antibodies to small molecules o Ritonavir-boosted nirmatrelvir o Remdesivir o Molnupiravir o Considerations for prescribing - Patient age and health status - Comorbidities - Polypharmacy and drug-drug interactions - Pregnancy - Time since COVID‑19 infection - Reproductive status and intentions o Emerging treatments · Drugs for hospitalized patients o Antivirals o Immunomodulatory agents o Supportive care, including antithrombotics o Emerging treatments · Patient case(s) |
|
Summary, conclusions, and best practice recap |
Learning Objectives
By the end of the session the participant will be able to:
- Explain the shifting virology of SARS-CoV-2 and its impact on COVID19 treatment options.
- Identify optimal treatment approaches for patients with COVID19 according to disease severity and risk factors, for inpatients and outpatients.
- Develop a treatment plan for a patient with mild or moderate COVID19 based on patient factors, comorbidities, and concomitant medications.
- Review approved, authorized, and investigational treatment options for eligible hospitalized and non-hospitalized patients with COVID19.
Accreditation
ACCME Activity #202523147
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.
Disclosures of Faculty: Michael S. Niederman, MD, Professor of Clinical Medicine, Weill Cornell Medical College, has received financial compensation for consulting work from: Gilead, Abbvie, Dompe, Merck, and Pfizer.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
Faculty WILL discuss off-label uses of a commercial product.
All relevant financial relationships have been mitigated.
ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Commercial Support Disclosure: This program is supported by an educational grant from Gilead.
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Additional Courses That Are Related To This Activity
Vaccine hesitancy and denial: A problem for the ages coming into sharp focus during the pandemic
The role of cultural competence in healthcare: cultural and linguistic competence